A20 Regulates the Therapeutic Effect of Anti-PD-1 Immunotherapy In
Total Page：16
File Type：pdf, Size：1020Kb
Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001866 on 9 December 2020. Downloaded from A20 regulates the therapeutic effect of anti- PD-1 immunotherapy in melanoma Weinan Guo,1 Jinyuan Ma,1 Sen Guo,1 Huina Wang,1 Sijia Wang,1,2 Qiong Shi,1 Lin Liu,1 Tao Zhao,1 Fengfan Yang,3 Shuyang Chen,4 Jianru Chen,1 Jianhong Zhao,1 Chen Yu,1 Xiuli Yi,1 Yuqi Yang,1 Jingjing Ma,1 Qingrong Ni,1 Guannan Zhu,1 1 1 Tianwen Gao, Chunying Li To cite: Guo W, Ma J, Guo S, ABSTRACT (PD-1)/programmed death ligand 1 (PD-L1) et al. A20 regulates the Background The therapeutic effect of immune have been demonstrated as a pair of major therapeutic effect of anti- PD-1 checkpoint blockers, especially the neutralizing immunotherapy in melanoma. immune checkpoint molecules and valuable antibodies of programmed cell death (PD-1) and its ligand 1 Journal for ImmunoTherapy therapeutic targets for melanoma treatment. programmed death ligand 1 (PD-L1), has been well verified of Cancer 2020;8:e001866. For instance, the binding of membrane doi:10.1136/jitc-2020-001866 in melanoma. Nevertheless, the dissatisfactory response rate and the occurrence of resistance significantly hinder PD- L1 on tumor cells to PD-1 on T cells the treatment effect. Inflammation- related molecules like evokes an immunosuppressive signal that ► Additional material is results in the dysfunction and even the apop- published online only. To view A20 are greatly implicated in cancer immune response, please visit the journal online but the role of tumorous A20 in antitumor immunity and tosis of cytotoxic T cells, thereby impairing 2 (http:// dx. doi. org/ 10. 1136/ jitc- immunotherapy efficacy remains elusive. antitumor immunity. Therefore, PD-1/ 2020- 001866). Methods The association between tumorous A20 PD- L1 blockade is in a position to disrupt expression and the effect of anti-PD-1 immunotherapy the interaction between tumor cells and T WG, JM, SG, HW and SW was determined by immunoblotting, immunofluorescence contributed equally. cells, which restores tumor- specific immune staining and flow cytometry analysis of primary tumor response.3 For melanoma patients receiving specimens from melanoma patients. Preclinical mouse anti- PD-1 antibody monotherapy, the median Accepted 18 November 2020 model, in vitro coculture system, immunohistochemical staining and flow cytometry analysis were employed to overall survival could be up to 32.7 months 4 investigate the role of A20 in regulating the effect of anti- after almost 5 years of follow-up. However, a PD-1 immunotherapy. Bioinformatics, mass spectrum proportion of 40%–60% of patients does not analysis and a set of biochemical analyzes were used to achieve any significant therapeutic response, figure out the underlying mechanism. © Author(s) (or their and some patients even show complete resis- Results We first discovered that upregulated A20 was 5 tance to PD-1/PD- L1 blockade. Accumula- http://jitc.bmj.com/ employer(s)) 2020. Re- use + permitted under CC BY- NC. No associated with impaired antitumor capacity of CD8 T tive evidence has revealed multiple primary commercial re- use. See rights cells and poor response to anti- PD-1 immunotherapy and acquired alterations leading to treatment and permissions. Published by in melanoma patients. Subsequent functional studies in resistance of immunotherapy, including low BMJ. preclinical mouse model and in vitro coculture system 1Department of Dermatology, proved that targeting tumorous A20 prominently improved mutational burden, defective antigenicity Xijing Hospital, Fourth Military the effect of immunotherapy through the invigoration and antigen presentation of tumor cell + Medical University, Xi'an, of infiltrating CD8 T cells via the regulation of PD- L1. and genomic dysregulation of interferon-γ on September 27, 2021 by guest. Protected copyright. Shaanxi, China 6–9 2 Mechanistically, A20 facilitated the ubiquitination and (IFN-γ) signaling pathway. These reports Department of Dermatology, degradation of prohibitin to potentiate STAT3 activation have prompted potential molecular profile Nanfang Hospital, Southern and PD- L1 expression. Moreover, tumorous A20 expression Medical University, Guangzhou, for predicting the treatment response and was highly associated with the ratio of Ki-67 percentage in Guangdong, China + + effective synergized therapeutic strategy for 3Department of Clinical circulating PD-1 CD8 T cells to tumor burden. cancer immunotherapy. Notably, tumor cells Conclusions Together, our findings uncover a novel Immunology, Xijing Hospital, can adaptively increase the expression of Fourth Military Medical crosstalk between inflammatory molecules and antitumor University, Xi'an, Shaanxi, China immunity in melanoma, and highlight that A20 can be PD-L1 or other immune checkpoints under 4Department of Pharmacology exploited as a promising target to bring clinical benefit to the control of IFN-γ after the treatment with and Experimental Therapeutics, melanomas refractory to immune checkpoint blockade. anti- PD-1 antibody, rendering melanomas Boston University School refractory to immunotherapy.10–12 Hence, of Medicine, Boston, the molecular mechanism underlying aber- Massachusetts, USA INTRODUCTION rant tumorous PD-L1 expression associated Correspondence to Eradication of immune destruction is a hall- with the resistance to immunotherapy in Professor Chunying Li; mark of cancer, which is primarily due to melanoma is in urgent need to be clarified to lichying@ fmmu. edu. cn the abnormal activation of immune check- improve the therapeutic efficacy. Dr Weinan Guo; points and the termination of antitumor Inflammation is closely related to the guown@ fmmu. edu. cn immune response. Programmed cell death development of various cancers including Guo W, et al. J Immunother Cancer 2020;8:e001866. doi:10.1136/jitc-2020-001866 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2020-001866 on 9 December 2020. Downloaded from melanoma, with its pivotal role in the regulation of METHODS cancer immune response demonstrated recently.13–15 A detailed description of the methods used in this study is To be specific, tumor necrosis factor-α (TNF-α) that is a available in online supplemental methods. common proinflammatory cytokine and its downstream pathway could induce tumor immune escape by elevating Statistical analysis the expressions of immune checkpoint molecules.13 16 All experiments were repeated at least three times unless On the other, TNF-α is also one of the major cytokines otherwise indicated. Error bars represent SE of the secreted by activated CD8+ T cells in tumor microenviron- mean. Student’s t- test was used to compare two groups ment that potentiates antitumor immune response.17 18 of independent samples. Liner regression was used to These reports highlight the vital impact of inflammatory confirm the correlation between two groups of depen- signaling on antitumor immunity, though the actual func- dent samples. P<0.05 was considered statistically signifi- tion remains controversial. A20 is a primary responsive cant. Kaplan- Meier analysis and log-rank (Mantel- Cox) gene of TNF-α and is documented as a crucial negative test were used to evaluate the statistical significance for mediator of inflammation as well as immune response in comparison of survival curves. All statistical analyzes were multiple immune cells.19 As a ubiquitin-editing enzyme, it performed with GraphPad Prism (GraphPad software is composed of an N- terminal OTU domain with deubiq- V.6.0, La Jolla, USA). uitinase activity and seven Cys2- Cys2 zinc finger C- ter- minal domains functioning as a ubiquitin ligase.20 The cooperative activity of these two ubiquitin-editing domains RESULTS mediates the negative regulatory role of A20 in NF-κB A20 expression is correlated with the clinical response to signaling,20 so that the genetic deficiency of TNFAIP3 anti-PD-1 antibody treatment in melanoma patients that encodes A20 protein can result in the onset and Previously, several transcriptomic and proteomic progression of multiple autoimmune diseases by ampli- researches have demonstrated that inflammation- related fying the pro-inflammator y NF-κB signaling.21 For cancer signals and molecules were highly correlated with the pathogenesis, previous investigations emphasized on A20 therapeutic effect of anti-PD-1 immunotherapy in mela- expressed in tumor- infiltrating immune cells to clarify its noma.26–29 Of note, in a cohort of 54 melanoma patients effect on antitumor immunity. In B16 mouse melanoma receiving anti- PD-1 antibody monotherapy, we noticed tumor model, silencing of A20 in dendritic cells (DCs) that a high fraction of non-responding patients had abun- enhanced NF-κB activity followed by elevated expres- dant expressions of immune gene markers like TNFAIP3 sion of interleukin 6 (IL-6), TNF-α and IL-12, leading to (encoding A20) and TLR3 in tumor, which was associated potentiated antitumor immune responses.22 In addition, with dampened immune response.29 A20 is a primary tumor- infiltrating CD8+ T with the deletion of A20 had responsive gene of TNF-α and is documented as a nega- stronger antitumor capacity by relieving the brake on tive mediator of inflammation. For cancer pathogenesis, NF-κB signaling pathway.23 Of note, A20 is also abun- previous investigations emphasized on A20 expressed in dantly expressed in tumor cells and can directly influence tumor- infiltrating immune cells and its effect on anti- http://jitc.bmj.com/ their biological behaviors.24